Treat with foresight



in action

EYLEA Mode of Action Video

2020/03/27 - Bayer Ophthalmology
Multi Targeted MOA


VEGF-binding affinity up to ~100-fold vs ranibizumab1



Unique multi-targeted trap is the only anti-VEGF that blocks all VEGFR-1 ligands, including VEGF and PGF1,a



Delivers long-lasting anti-VEGF activity up to 2x longer than ranibizumab2-4



in the treatment of DME,

Even with complete VEGF blockade by ranibizumab or bevacizumabb, PGF would still be available to bind VEGFR-1 allowing, for example, further escalation of inflammation in DME1,5-7

  • PGF only binds VEGFR-1.
  • Bevacizumab has no marketing authorization for use in ophthalmic indications.


  • Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15;171-185.
  • Muether PS, Hermann MM, Dröge K, Kirchhof B, Fauser S. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am J Ophthalmol. 2013;156:989-993.
  • Fauser S, Muether PS. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol. 2016;100:1494-1498.
  • Fauser S, Schwabecker V, Muether PS. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol. 2014;158:532-536.
  • Al Kahtani E, Xu Z, Al Rashead S, et al. Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatment. Eye (Lond). 2017;31:529-536.
  • Nguyen QD, De Falco S, Behar-Cohen F, et al. Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. Acta Ophthalmol. 2018;e1-e9.
  • Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost. 2003;1:1356-1370.

This website contains information on EYLEA® (aflibercept solution for injection) which is based on the Summary of Product Characteristics (SPC) as approved by the European Commission. It is intended to provide information to an international audience outside the USA and UK. In countries outside the EU the local Product Information applies.

PP-EYL-ALL-0513-1. Last updated on 29/02/2020